| __timestamp | AstraZeneca PLC | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 60716000 |
| Thursday, January 1, 2015 | 11451000000 | 119401000 |
| Friday, January 1, 2016 | 9739000000 | 140879000 |
| Sunday, January 1, 2017 | 10543000000 | 199243000 |
| Monday, January 1, 2018 | 10362000000 | 240636000 |
| Tuesday, January 1, 2019 | 11848000000 | 264359000 |
| Wednesday, January 1, 2020 | 11693000000 | 260583000 |
| Friday, January 1, 2021 | 15680000000 | 324951000 |
| Saturday, January 1, 2022 | 18955000000 | 372766000 |
| Sunday, January 1, 2023 | 18025000000 | 378378000 |
| Monday, January 1, 2024 | 20532000000 | 396826000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, AstraZeneca PLC and Bio-Techne Corporation have demonstrated contrasting approaches to SG&A cost management.
AstraZeneca, a global pharmaceutical giant, has seen its SG&A expenses fluctuate, peaking in 2022 with a 44% increase from 2014. In contrast, Bio-Techne, a smaller biotech firm, has consistently managed its SG&A costs, with a steady increase of approximately 550% over the same period. This suggests a more controlled and strategic approach to scaling operations.
While AstraZeneca's larger scale might justify higher expenses, Bio-Techne's efficient cost management highlights its agility in the biotech sector. As we look to 2024, Bio-Techne's continued growth in SG&A expenses, despite missing data for AstraZeneca, could signal a strategic expansion phase.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Gilead Sciences, Inc.
Selling, General, and Administrative Costs: AstraZeneca PLC vs Axsome Therapeutics, Inc.
AstraZeneca PLC vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
AstraZeneca PLC and Taro Pharmaceutical Industries Ltd.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Bio-Techne Corporation
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Bio-Techne Corporation
Viatris Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Bio-Techne Corporation vs BioMarin Pharmaceutical Inc. Trends and Insights
Bio-Techne Corporation and Halozyme Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Bio-Techne Corporation vs Amneal Pharmaceuticals, Inc. Trends and Insights
Bio-Techne Corporation vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Bio-Techne Corporation vs BioCryst Pharmaceuticals, Inc. Trends and Insights